单酰基甘油酰基转移酶2抑制剂的作用机理与相关药物研究进展  

Progress in the research of MGAT2 inhibitors and their mechanisms of action

作　　者：邢维伟[1] 周卓 XING Wei-wei;ZHOU Zhuo(Patent Office of the State Intellectual Property Office,Beijing 100088,China;China National Pharmaceutical Group Corporation,Beijing 100191,China)

机构地区：[1]国家知识产权局专利局,北京100088 [2]中国医药集团有限公司,北京100191

出　　处：《中国新药杂志》2018年第20期2367-2376,共10页Chinese Journal of New Drugs

摘　　要：2003年研究人员发现了单酰基甘油酰基转移酶2(MGAT2)在脂肪合成中的作用和机理,由此展开了对MGAT2抑制剂相关药物的研究。2009—2018年,已经研究开发出了多种类型的MGAT2抑制剂并在动物实验取得了较好的脂肪吸收抑制效果,可用于治疗诸如肥胖症、2型糖尿病及血脂异常等代谢综合征。MGAT2抑制剂类药物是一种具有重要价值的潜在药物,值得临床及相关新药研发人员关注。The action and mechanisms of MGAT2 in the synthesis of fat are reported in 2003. The related research about MGAT2 inhibitors is started. From 2019 to 2018,various types of MGAT2 inhibitors have been developed and achieved favorite fat absorption inhibition in animal experiments,such as treat obesity,type 2 diabetes,dyslipidemia and other metabolic diseases. MGAT2 inhibitors drugs have important potential value and deserve the attention of relevant researchers.

关 键 词：单酰基甘油酰基转移酶2 抑制剂 糖尿病 代谢 肥胖 

分 类 号：R96[医药卫生—药理学]